Global Brain Disease Imaging and Software Market – Industry Trends and Forecast to 2031

Análise e tamanho do mercado de imagens e software de doenças cerebrais

Segundo a Organização Mundial de Saúde (OMS), a nível global, cerca de 50 milhões de pessoas sofrem de demência, com quase 10 milhões de novos casos a cada ano. A doença de Alzheimer é responsável por 60-70% destes casos, a prevalência global da doença de Parkinson é estimada em cerca de 1% da população com mais de 60 anos, sendo que a incidência aumenta com a idade. Segundo a OMS, ocorrem aproximadamente 15 milhões de novos casos de AVC por ano, dos quais cerca de 5 milhões resultam em morte. A prevalência global da esclerose múltipla (EM) está estimada em cerca de 2,3 milhões de pessoas, com uma variação geográfica significativa. Além disso, a Epilepsy Foundation refere que cerca de 3,4 milhões de pessoas nos Estados Unidos têm epilepsia, com aproximadamente 150.000 novos casos diagnosticados a cada ano.

A Data Bridge Market Research analisa que o mercado global de imagiologia e software de doenças cerebrais, que foi de 14,22 mil milhões de dólares em 2023, subiria para 21,38 mil milhões de dólares até 2031 e deverá passar por um CAGR de 5,2 % durante o período de previsão. Este indica o valor de mercado. “Dispositivos de imagem” domina o segmento de tipos de mercado de software e imagens de doenças cerebrais devido à crescente procura por melhores métodos de tratamento nos doentes. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Definição de mercado

As imagens e o software de doenças cerebrais referem-se à utilização de várias técnicas de imagem e ferramentas de software especializadas para visualizar, analisar e interpretar estruturas e funções cerebrais para diagnosticar, tratar e monitorizar distúrbios e doenças neurológicas. O software de imagiologia de doenças cerebrais desempenha um papel crucial no processamento e análise da grande quantidade de dados de imagiologia gerados por estas modalidades. Estas soluções de software incluem frequentemente algoritmos e ferramentas avançadas para reconstrução, segmentação, registo, visualização e análise quantitativa de imagens cerebrais. Permitem aos profissionais de saúde, como radiologistas, neurologistas e neurocirurgiões, identificar com precisão anormalidades, como tumores, lesões, áreas isquémicas ou alterações estruturais, e avaliar a função cerebral e a conectividade.

Dinâmica do mercado de imagens e software de doenças cerebrais

Motoristas

• Aumento dos avanços tecnológicos

Os avanços contínuos nas tecnologias de imagem e nas capacidades de software são cruciais para impulsionar o mercado. Inovações como técnicas de imagem de alta resolução, modalidades de imagem funcional como fMRI (ressonância magnética funcional), PET (tomografia por emissão de positrões) e algoritmos de software avançados para análise de imagens contribuem para melhorar o diagnóstico, o planeamento do tratamento e o monitorização de doenças cerebrais. À medida que a tecnologia evolui, permite uma melhor visualização e compreensão das estruturas e funções cerebrais, impulsionando a procura por soluções de imagem e software avançados em ambientes clínicos.

• Aumento da prevalência de perturbações cerebrais

The increasing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, and stroke worldwide is a significant driver of the Brain Disease Imaging and Software Market. As the global population ages and lifestyles change, the incidence of these conditions is on the rise, creating a growing demand for diagnostic tools and software solutions that can accurately detect, diagnose, and monitor brain diseases at an early stage. The need for timely and precise diagnosis drives healthcare providers and researchers to invest in advanced imaging technologies and software solutions to improve patient outcomes and quality of life.

Opportunities

• Personalized Medicine and Precision Imaging

There is an increasing trend towards personalized medicine in healthcare, including neurology. Advanced imaging techniques and software solutions can facilitate personalized diagnosis and treatment planning by providing detailed insights into an individual's brain structure, function, and pathology. By incorporating patient-specific data, such as genetic information, biomarkers, and clinical history, imaging and software technologies can help clinicians tailor treatment strategies to each patient's unique needs. This presents an opportunity for companies to develop specialized imaging modalities and software algorithms that enable personalized diagnosis, prognosis, and treatment monitoring for various brain diseases, leading to more effective and targeted therapies.

• Integration of Artificial Intelligence (AI) and Machine Learning

AI and machine learning technologies have the potential to revolutionize brain disease imaging and software by improving the accuracy, efficiency, and automation of diagnostic processes. AI algorithms can analyze large volumes of imaging data faster and more accurately than traditional methods, helping clinicians identify subtle patterns and biomarkers indicative of specific brain disorders. In addition, machine learning algorithms can learn from past cases to enhance diagnostic accuracy and predict patient outcomes. Companies can capitalize on this opportunity by developing AI-powered imaging solutions that assist radiologists and neurologists in interpreting imaging studies, detecting abnormalities, predicting disease progression, and optimizing treatment plans. Integrating AI into brain disease imaging and software can streamline workflows, reduce interpretation errors, and ultimately improve patient care outcomes.

Restraints/Challenges

• Cost Constraints and Healthcare Budgets

One restraint is the high cost associated with advanced imaging technologies and software solutions. These technologies often require substantial investments in equipment, software development, maintenance, and training. Additionally, reimbursement policies and healthcare budget constraints in many regions may limit the adoption of expensive imaging modalities and software upgrades. Healthcare providers and institutions may hesitate to invest in new technologies without clear evidence of cost-effectiveness or improved patient outcomes. As a result, the high upfront costs of brain disease imaging and software solutions can act as a barrier to market growth, particularly in resource-constrained settings or regions with limited access to healthcare funding.

• Data Privacy and Regulatory Compliance

A significant challenge in the Brain Disease Imaging and Software Market is ensuring compliance with data privacy regulations and maintaining the security of sensitive patient information. Brain imaging data contains highly personal and confidential information about patients' neurological health, making it subject to strict privacy regulations such as HIPAA (Health Insurance Portability and Accountability Act) in the United States and GDPR (General Data Protection Regulation) in the European Union. Developing imaging and software solutions that meet these regulatory requirements while still enabling efficient data sharing and collaboration among healthcare providers and researchers is a complex challenge. Companies must invest in robust data security measures, encryption techniques, and compliance frameworks to protect patient privacy and ensure regulatory compliance. Failure to address these concerns adequately can hinder market adoption and erode trust among healthcare stakeholders.

This brain disease imaging and software market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Brain Disease Imaging and Software market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In Mar 2021, DiA Imaging Analysis declared its collaboration with Royal Phillips to offer high-quality ultrasound imaging with artificial intelligence (AI)-based image quantification. Al-based solutions are applied to a range of applications, including image detection, diagnosis and decision support, image acquisition, reporting and communication, triage, image analysis, and predictive analysis and risk assessment
• In Jan 2022, New MRI technology is developed by Siemens company in alliance with researchers at The Ohio State University College, will magnify imaging access for patients with implanted medical devices, claustrophobia, and severe obesity

Brain Disease Imaging and Software Market Scope

The brain disease imaging and software market is segmented on the basis of type, application, patient type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Imaging Devices
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Electroencephalography (EEG)
• Software
  • Detecting brain abnormalities
  • Measuring brain volume
  • Tracking disease progression
  • Aiding in surgical planning

Application

• Alzheimer's Disease
• Dementia
• Stroke
• Multiple sclerosis
• Parkinson's disease
• Brain Tumors
• Epilepsy
• Traumatic Brain Injury (TBI)

Patient Type

• Adults
• Pediatrics
• Infants

End User

• Hospitals and Clinics
• Ambulatory Surgery Centers
• Diagnostic Imaging Centers
• Research Institutions

Brain Disease Imaging and Software Market Regional Analysis/Insights

The brain disease imaging and software market is analysed and market size insights and trends are provided by country, type, application, patient type, and end user as referenced above.

The countries covered in the brain disease imaging and software market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

North America is expected to dominate the brain disease imaging and software market because of the strong base of healthcare facilities, the strong presence of major players, the extraordinary healthcare infrastructure, and the large pool of people.   

Asia-Pacific is expected to witness significant growth due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Brain Disease Imaging and Software market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Brain Disease Imaging and Software market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Brain Disease Imaging and Software market.

Competitive Landscape and Brain Disease Imaging and Software Market Share Analysis

The brain disease imaging and software market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Quantib (Netherlands)
• Brainomix (U.K.)
• General Electric Company (U.S.)
• Imaging Biometrics, LLC (U.S.)
• United Imaging Healthcare Co. Ltd. (China)
• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• Canon Inc. (Japan)
• Vuno Co. Ltd. (South Korea)
• Aspect Imaging (Israel)
• IXICO (U.K.)
• Fujifilm Holdings Corporation (Japan)

SKU-70809